^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peripheral T-cell Lymphoma
    Drug:Folotyn (pralatrexate) (THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    FOLOTYN is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Peripheral T-cell Lymphoma: Second-line therapy (with intention to proceed to transplant) and subsequent therapy...Preferred regimens…Pralatrexate